natgillin/translations-raw huggingface dataset:
Although the potential for interactions with medicinal products seems low, for concomitant treatment with medicinal products with a narrow therapeutic window, the clinical effect and adverse events should be monitored, on initiation or dose- adjustment of either Velphoro or the concomitant medicinal product, or the physician should consider measuring blood levels.
Čeprav se zdi možnost za medsebojno delovanje z drugimi zdravili majhna, je treba pri sočasnem zdravljenju z zdravili z ozko terapevtsko širino ob začetku jemanja ali prilagoditvi odmerka zdravila Velphoro ali zdravila, ki se jemlje sočasno, spremljati klinični učinek in neželene dogodke ali pa mora zdravnik preučiti smiselnost merjenja ravni v krvi.
Although the precise mode of action is unclear, delamanid is known to block the production of methoxy-mycolic and keto-mycolic acids, two essential components of the cell walls of M. tuberculosis, which will cause the bacteria to die.
Čeprav natančen način delovanja ni jasen, je znano, da delamanid zavira tvorbo metoksimikolne in ketomikolne kisline, dveh esencialnih sestavin celične stene bakterije M. tuberculosis, kar povzroči odmrtje bakterij.
Although the product may be safely administered to cats infected with adult heartworms, no therapeutic effect against adult Dirofilaria immitis has been established.
Čeprav se lahko to zdravilo za uporabo v veterinarski medicini varno uporablja tudi pri mačkah, okuženih z odraslimi srčnimi glistami, na odraslo Dirofilaria immitis nima terapevtskega učinka.
Although the risk of immunocompromised humans becoming infected with Bordetella bronchiseptica is extremely low, it is advised that cats, which are in close contact with immunocompromised humans are not vaccinated with this vaccine.
Čeprav je nevarnost, da bi se osebe z zmanjšano imunsko odpornostjo okužile z Bordetello bronchiseptico izjemno majhna, ne priporočamo cepljenja mačk, ki so v tesnem stiku z njimi.
Although the studies showed that Imvanex is expected to protect against smallpox, it is not possible to determine from study results the exact level of protection or how long the protection would last.
Čeprav so študije pokazale, da cepivo Imvanex verjetno ščiti pred črnimi kozami, iz rezultatov študije ni bilo mogoče ugotoviti, kakšna je natančna stopnja zaščite ali kako dolgo traja.
Although the TRA 2°P - TIMI 50 trial was not designed to evaluate the relative benefit of Zontivity in individual patient subgroups, the benefit was most apparent in patients who were enrolled on the basis of a recent MI as indicated by a history of spontaneous MI ≥2 weeks but 12 months prior (post-MI or PAD patient population) with no history of stroke or TIA.
Čeprav preskušanje TRA 2°P – TIMI 50 ni bilo namenjeno ugotavljanju relativne koristi zdravila Zontivity v posameznih podskupinah bolnikov, je bila korist najbolj očitna pri bolnikih, vključenih zaradi nedavnega MI, tj. z anamnezo spontanega MI ≥ 2 tedna, toda  12 mesecev prej (populacija bolnikov po MI ali PAD) in brez možganske kapi ali TIA v anamnezi.
Although the use of ellaOne does not contraindicate the continued use of regular hormonal contraception, ellaOne may reduce its contraceptive action (see section 4.5).
Čeprav uporaba zdravila ellaOne ne kontraindicira nadaljnje uporabe redne hormonske kontracepcije, lahko ellaOne zmanjša njeno kontracepcijsko delovanje (glejte poglavje 4.5).
Although there are limited clinical data on the use of Emtricitabine/Tenofovir disoproxil Zentiva in pregnant women, it is not usually used unless absolutely necessary.
Čeprav so na voljo nezadostni klinični podatki o uporabi zdravila Emtricitabin/dizoproksiltenofovirat Zentiva pri nosečnicah, se zdravila Emtricitabin/dizoproksiltenofovirat Zentiva ponavadi ne uporablja, razen če je nujno potrebno.
Although there are limited clinical data on the use of Truvada in pregnant women, it is not usually used unless absolutely necessary.
Čeprav so na voljo nezadostni klinični podatki o uporabi zdravila Truvada pri nosečnicah, se zdravilo Truvada ponavadi ne uporablja, razen če je nujno potrebno.
Although there is a 49% decrease in Cmax of nateglinide in dialysis patients, the systemic availability and half-life in diabetic subjects with moderate to severe renal insufficiency (creatinine clearance 15–50 ml/min) was comparable between renal subjects requiring haemodialysis and healthy subjects.
Čeprav se pri dializnih bolnikih Cmax nateglinida zmanjša za 49 %, sta bila sistemska uporabnost in razpolovni čas pri sladkornih bolnikih z zmerno do hudo ledvično insuficienco (očistek kreatinina 15-50 ml/min) pri ledvičnih bolnikih, ki potrebujejo hemodializo, in pri zdravih osebah primerljiva.
Although there is a potential for the development of progressive multifocal leukoencephalopathy (PML), no case of PML has been reported in the pivotal study.
Kljub možnosti za pojav progresivne multifokalne levkoencefalopatije pa v ključni študiji niso zabeležili nobenega primera multifokalne levkoencefalopatije.
Although there is no clinical evidence, theoretical data suggest that antioxidants (e.g. beta-carotene) or medicinal products which scavenge free radicals (e.g. dimethylsulfoxide (DMSO), formate, mannitol or alcohol) might quench the activated oxygen species generated by verteporfin, resulting in decreased verteporfin activity.
Čeprav ni na voljo kliničnih dokazov, bi po teoretičnih podatkih lahko antioksidanti (na primer beta- karoten) ali zdravila, ki lovijo proste radikale (na primer dimetilsulfoksid (DMSO), format, manitol ali alkohol) nevtralizirali aktivirane kisikove zvrsti, ki nastajajo zaradi verteporfina, kar bi zmanjšalo delovanje verteporfina.
Although there was no difference between patients receiving Esbriet compared to placebo in change from Baseline to Week 72 of distance walked during a six minute walk test (6MWT) by the prespecified rank ANCOVA, in an ad hoc analysis, 37% of patients receiving Esbriet showed a decline of ≥50 m in 6MWT distance, compared to 47% of patients receiving placebo in PIPF-004.
Čeprav med bolniki, ki so prejemali zdravilo Esbriet, in tistimi, ki so prejemali placebo, ni bilo razlik pri spremembi od izhodiščne vrednosti do 72. tedna glede prehojene razdalje v šestminutnem testu hoje (6MWT) s predhodno določenim rangom ANCOVA, se je v ad hoc analizi pri 37 % bolnikov, ki so prejemali zdravilo Esbriet, pri šestminutnem testu hoje pokazal padec razdalje ≥ 50 m v primerjavi s 47 % tistih, ki so prejemali placebo v študiji PIPF–004.
Although there was no significant difference between the two groups in the percentages of subjects with antibody concentration  0.20 g/mL (ELISA), the percentages of subjects for serotypes 6B and 23F were lower than for the other vaccine serotypes (Table 7 and Table 8).
Čeprav se odstotek preiskovancev s koncentracijo protiteles 0,20 g/ml (ELISA) med skupinama ni bistveno razlikoval, so bili odstotki preiskovancev za serotipa 6B in 23F manjši kot za ostale serotipe v cepivu (preglednica 7 in preglednica 8).
Although there were limitations in the studies, including lack of control group and low number of patients, the Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Darzalex’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Kljub omejitvam v študijah, vključno s pomanjkanjem kontrolnih skupin in majhnim številom bolnikov, je Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji zaključil, da so koristi zdravila Darzalex večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
Although there were no completed suicides, there was one suicidal attempt in a varenicline-treated subject whose lifetime history included several similar attempts.
Čeprav dejanskih samomorov ni bilo, so pri preiskovancu, ki je prejemal vareniklin, poročali o enem poskusu samomora; preiskovanec je v preteklosti večkrat poskušal storiti samomor.
Although these biological side effects have not been reported in humans, the use of a low mechanical index and end- diastolic triggering is recommended.
Čeprav o teh bioloških neželenih učinkih niso poročali pri človeku, je priporočljiva uporaba nizkega mehanskega indeksa in proženje na koncu diastole.
Although these biological side effects have not been reported in humans, the use of a low mechanical index is recommended.
Čeprav ti neželeni učinki niso bili zapaženi pri ljudeh, se priporoča uporabo nizkega mehaničnega indeksa.
Although these doses are not expected to exactly reproduce the pharmacokinetic profile of tenofovir in patients with normal renal function receiving tenofovir disoproxil (as fumarate) 245 mg film-coated tablets, they are considered to represent the best balance of benefit and risk for patients with renal impairment.
Ne pričakuje se, da bi ti odmerki natančno ponovili farmakokinetični profil tenofovirja pri bolnikih z normalno ledvično funkcijo, ki so prejemali dizoproksiltenofovirat (v obliki dizoproksiltenofovirijevega fumarata) 245 mg filmsko obložene tablete, temveč se obravnava, da predstavljajo najboljše ravnovesje med koristmi in tveganji za bolnike z ledvično okvaro.
Although these have not been seen in clinical trials involving UCD patients, high PAA levels should be suspected in patients with unexplained somnolence, confusion, nausea and lethargy who have normal or low ammonia.
Čeprav te manifestacije niso bile opažene v kliničnih preskušanjih, ki so vključevala bolnike z UCD, je treba pri bolnikih z nepojasnjeno somnolenco, zmedenostjo, slabostjo in letargijo, pri katerih je raven amoniaka normalna ali nizka, posumiti na visoke ravni PAA.
Although these simulated results have not been confirmed in clinical trials, this high dose may be considered in the presence of the Q148 + 2 secondary mutations from G140A/C/S, E138A/K/T, L74I in patients with overall limited treatment options due to advanced multi class resistance.
Čeprav ti simulirani rezultati niso bili potrjeni v kliničnih preskušanjih, ta visoki odmerek morda lahko pride v poštev v prisotnosti Q148 +  2 sekundarnih mutacij G140A/C/S, E138A/K/T, L74I pri bolnikih, ki imajo v celoti omejene možnosti zdravljenja zaradi napredovale odpornosti proti več skupinam.
Although they have theoretically interesting hormonal effects, their concentrations during toremifene treatment are too low to have any major biological importance.
Četudi imajo ti teoretično zanimive hormonske učinke, pa so njihove koncentracije med zdravljenjem s toremifenom prenizka, da bi lahko imeli kak večji biološki pomen.
Although this complication is very rare, you should be aware that if you develop it, you would need to have regular blood transfusions, possibly lifelong, to treat your anaemia and the Retacrit therapy would have to be discontinued.
Čeprav se ta zaplet pojavlja zelo redko, se morate zavedati, da boste v primeru, če bi prišlo do njega, potrebovali za zdravljenje anemije redne transfuzije krvi, morda celo življenje, in da se bo zdravljenje z zdravilom Retacrit prekinilo.
Although Toujeo contains the same active substance as insulin glargine 100 units/ml, these medicines are not interchangeable.
Zdravilo Toujeo sicer vsebuje isto zdravilno učinkovino kot insulin glargin 100 enot/ml, vendar ti zdravili nista medsebojno zamenljivi.
Although transplantation rate was not a study endpoint, 10/61 patients (16%) went on to receive a HSCT after treatment with clofarabine (3 after achieving a CR, 2 after a CRp,
Čeprav stopnja transplantacije ni bila končna točka študije, je po zdravljenju s klofarabinom 10/61 bolnikov (16 %) prejelo HSCT (3 po PR, 2 po PRt, 3 po DR, zdravljenje
Although treatment will reduce the spread of infection, it will not be effective against the clinical signs of infection in already infected animals.
Čeprav zdravljenje upočasni širjenje okužbe, ne bo učinkovito zoper klinične znake okužbe pri že okuženih živalih.
Although treatment with edoxaban does not require routine monitoring, the effect on anticoagulation can be estimated by a calibrated quantitative anti-Factor Xa assay which may help to inform clinical decisions in particular situations as, e.g. overdose and emergency surgery (see also section 5.2).
Čeprav pri zdravljenju z edoksabanom ni potrebno rutinsko spremljanje, lahko njegov vpliv na antikoagulacijo ocenimo s kalibriranim kvantitativnim testom anti-Xa, ki lahko v določenih primerih, npr. pri prevelikem odmerjanju in nujnem kirurškem posegu, pomaga pri klinični odločitvi (glejte tudi poglavje 5.2).
Although treatment with rivaroxaban does not require routine monitoring of exposure, rivaroxaban levels measured with a calibrated quantitative anti-factor Xa assay may be useful in exceptional situations where knowledge of rivaroxaban exposure may help to inform clinical decisions, e.g., overdose and emergency surgery (see sections 5.1 and 5.2).
Čeprav pri zdravljenju z rivaroksabanom ni potrebno rutinsko spremljanje koncentracije rivaroksabana v krvi, je lahko v izjemnih primerih, ko bi lahko podatki o koncentraciji rivaroksabana v krvi pomagali pri klinični odločitvi (npr. pri prekomernem odmerjanju in nujnem kirurškem posegu), v pomoč določanje vrednosti rivaroksabana s kalibriranim kvantitativnim merjenjem aktivnosti anti-FXa (glejte poglavji 5.1 in 5.2).
Although very limited data are available for elderly patients with an R117H-CFTR mutation treated with ivacaftor in study 6, no dose adjustment is considered necessary unless moderate hepatic impairment exists.
Čeprav so na voljo zelo omejeni podatki za starejše bolnike z mutacijo R117H-CFTR, zdravljenih z ivakaftorjem v študiji 6, velja, da prilagajanje odmerka ni potrebno, če ni prisotna zmerna okvara jeter.
Although Warfarin-induced skin necrosis can occur in any patient during the initiation of oral anticoagulant therapy, individuals with congenital protein C deficiency are particularly at risk. (See section 4.2).
Čeprav se lahko med uvedbo peroralne antikoagulantne terapije pri kateremkoli bolniku pojavi varfarinska kožna nekroza, so še posebej ogroženi posamezniki s kongenitalnim pomanjkanjem proteina C (glejte poglavje 4.2).
Although Xeplion was not studied on patients with hepatic impairment, no dose adjustment is required in patients with mild or moderate hepatic impairment.
Čeprav zdravila Xeplion niso preučevali pri bolnikih z jetrno okvaro, pri bolnikih z blago ali zmerno jetrno okvaro ni treba prilagajati odmerka.
Although YENTREVE is not indicated for the treatment of depression, its active ingredient (duloxetine) also exists as an antidepressant medicinal product.
Čeprav zdravilo YENTREVE ni indicirano za zdravljenje depresije, njegova zdravilna učinkovina (duloksetin) obstaja tudi kot antidepresiv.
Although YENTREVE is not indicated for the treatment of depression, its active ingredient (duloxetine) also exists as an antidepressant medicinal product.
Čeprav zdravilo YENTREVE ni indicirano za zdravljenje depresije, njegova zdravilna učinkovina (duloksetin) obstaja tudi kot antidepresivno zdravilo.
Although YENTREVE is not indicated for the treatment of depression, its active ingredient (duloxetine) is used as an antidepressant medicine.
Čeprav zdravilo YENTREVE ni indicirano za zdravljenje depresije, se njegova zdravilna učinkovina (duloksetin) uporablja tudi kot antidepresiv.
Although you should focus on the calories and fat that you eat, it is important to eat a balanced diet.
Čeprav se morate osredotočiti na kalorije in maščobe, ki jih pojeste, je zelo pomembno da je vaša dieta uravnotežena.
Although Zaltrap is associated with significant side effects, which can be severe enough to force treatment to be stopped, the results of the large main study show that there is a small but clinically significant benefit in prolonging the life of treated patients in whom previous treatment failed.
Čeprav je zdravilo Zaltrap povezano z znatnimi neželenimi učinki, ki so lahko dovolj hudi, da povzročijo prenehanje zdravljenja, rezultati obsežne glavne študije kažejo, da ima zdravilo majhne, vendar klinično pomembne koristi pri podaljšanju življenja bolnikov, pri katerih predhodno zdravljenje ni bilo uspešno.
Although, renal failure could be a worsening of the underlying disease and all cases were confounded by concurrent conditions (sepsis, infection, tumor lysis syndrome), pre-existing kidney disease or concomitant nephrotoxic medications (aminosides, amphotericin, vancomycin, cytarabine, melphalan to name a few), a causal relationship with clofarabine could not be excluded, especially based on a plausible time to onset and on a plausible biological mechanism of action.
Čeprav bi bila lahko odpoved ledvic poslabšanje osnovne bolezni in čeprav so bile v vseh primerih kot moteči dejavnik prisotne sočasne bolezni (sepsa, okužba, sindrom lize tumorja), že prej obstoječa bolezen ledvic ali sočasna uporaba nefrotoksičnih zdravil (aminozidov, amfotericina, vankomicina, citarabina, melfalana, če navedemo le nekatera), vzročne povezanosti s klofarabinom ni mogoče izključiti, zlasti glede na prepričljiv čas do pojava in prepričljiv biološki mehanizem delovanja.
Although, the clinical relevance of this finding is not completely clear, patients should be advised to cover the transdermal patch application site if there is a risk of exposure to sunlight throughout the period of wear and for 10 days following its removal (see section 4.4).
Čeprav klinični pomen te ugotovitve ni popolnoma jasen, je treba bolnikom svetovati, naj mesto uporabe transdermalnega obliža pokrivajo, če obstaja nevarnost izpostavljanja sončni svetlobi, in sicer ves čas obdobja nošenja obliža in še 10 dni po njegovi odstranitvi (glejte poglavje 4.4).
ALTITUDE (Aliskiren Trial in Type 2 Diabettes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.
Študija ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) je preučevala koristi dodatka aliskirena standardnemu zdravljenju z zaviralcem ACE ali blokatorjem receptorjev angiotenzina II pri bolnikih s sladkorno boleznijo tipa 2 in kronično boleznijo ledvic, kardiovaskularno boleznijo ali obojim.
Altogether, 87 complete and partial responses were observed, with 13 of these occurring during cycles 5 and 6 and 3 occurring thereafter.
Skupno so zasledili 87 popolnih ali delnih odzivov, od česar se jih je 13 pojavilo med cikloma 5 ali 6, trije pa v poznejših ciklih.
ALU BLISTER
PRETISNI OMOT (ALU)
Alu/Alu blister
Alu/Alu pretisni omot
Alu/Alu blister containing 10 film-coated tablets.
Alu/Alu pretisni omot vsebuje10 filmsko obloženih tablet.
Alu/alu blister containing one hard capsule.
Pretisni omot iz aluminija, ki vsebuje eno trdo kapsulo.
ALU/ALU blister PVC/ALU blister
Pretisni omot iz ALU/ALU Pretisni omot iz PVC/ALU
Alu/Alu blister.
Alu/Alu pretisni omot.
Alu/Alu blister.
Pretisni omoti (aluminij/aluminij).
Alu/Alu blisters
Pretisni omoti Alu/Alu
Alu/Alu blisters
Pretisni omoti iz aluminija/aluminija
Alu/Alu blisters (calendar blisters or perforated unit dose blisters).
Alu/alu pretisni omoti (koledarski pretisni omoti ali perforirani enoodmerni pretisni omoti).
Alu/Alu blisters 2 years.
Pretisni omoti iz aluminija/aluminija 2 leti
Alu/Alu blisters.
Alu-Alu pretisni omot.
alu/PET/paper) vial (glass)
viala (steklena)
alu/PVC/alu) blister (PA-
pretisni omot (PA aluminija/PVC/aluminija)
aluminium
zamaškom
Aluminium (as hydroxide) 1.4 mg
Aluminij (v hidroksidni obliki) 1,4 mg
Aluminium + Dessicant – Aluminium blisters.
Aluminij + sušilno sredstvo – aluminijasti pretisni omoti.
Aluminium / Aluminium or PVC/Aluminium blisters placed into cardboard boxes containing 20, 30, 60 or 90 tablets.
Pretisni omoti iz aluminija/aluminija ali PVC/aluminija, vloženi , vložene v kartonske škatle, ki vsebujejo 20, 30, 60 ali 90 tablet.
Aluminium /Aluminium or PVC/Aluminium blisters placed into cardboard boxes containing 30 or 60 tablets.
Pretisni omoti iz aluminija/aluminija ali PVC/aluminija, vloženi , vložene v kartonske škatle, ki vsebujejo 30 ali 60 tablet.
Aluminium /Aluminium peel-push blisters containing 14 dispersible tablets.
Luščljiv pretisni omot iz aluminija/aluminija s 14 disperzibilnimi tabletami.
aluminium and magnesium hydroxide antacid (raltegravir 400 mg Twice Daily)
antacid z magnezijevim in aluminijevim hidroksidom (raltegravir 400 mg dvakrat na dan)
aluminium and magnesium hydroxide antacid /lamivudine
antacid z magnezijevim in aluminijevim hidroksidom/lamivudin
aluminium and magnesium hydroxide antacid /raltegravir (raltegravir 400 mg Twice Daily)
antacid z magnezijevim in aluminijevim hidroksidom/raltegravir (raltegravir 400 mg dvakrat na dan)
Aluminium blister of 7 tablets (120 mg)
Pretisni omot iz aluminijaste folije po 7 tablet (120 mg)
Aluminium blister of 7 tablets (15 mg)
Pretisni omot iz aluminijaste folije po 7 tablet (15 mg)
Aluminium blister of 7 tablets (60 mg)
Pretisni omot iz aluminijaste folije po 7 tablet (60 mg)
Aluminium blisters
Aluminijast pretisni omot
Aluminium blisters (each strip containing 8 tablets) packaged into an outer cardboard box.
Aluminijasti pretisni omoti (vsak pretisni omot vsebuje 8 tablet) pakirani v kartonsko škatlo.
Aluminium blisters each containing one 40 mg capsule.
Pet aluminijastih pretisnih omotov, ki vsebujejo po eno 40 mg kapsulo.
Aluminium blisters each containing one 80 mg capsule.
Pet aluminijastih pretisnih omotov, ki vsebujejo po eno 80 mg kapsulo.
Aluminium blisters in cardboard cartons containing 14, 28 and 84 film-coated tablets.
Aluminijasti pretisni omoti v kartonskih škatlah, ki vsebujejo 14, 28 in 84 filmsko obloženih tablet.
Aluminium blisters in cardboard cartons containing 14, 28, 30 and 84 film-coated tablets.
Aluminijasti pretisni omoti v kartonskih škatlah, ki vsebujejo 14, 28, 30 in 84 filmsko obloženih tablet.
Aluminium blisters in cardboard cartons containing 14, 28, 30 and 84 film-coated tablets.
Aluminijasti pretisni omoti v kartonskih škatlah, ki vsebujejo 14, 28,30 in 84 filmsko obloženih tablet.
aluminium cap
zamaškom
aluminium cap
zaporko
Aluminium foil laminated sachet containing 40 g or 400 g.
Vrečka iz laminirane aluminijeve folije, ki vsebuje 40 g ali 400 g.
Aluminium foil laminated sachet containing 40 g, 160 g or 400 g of granules.
Vrečka iz laminirane aluminijeve folije, ki vsebuje po 40 g, 160 g ali 400 g zrnc.
Aluminium foil laminated sachets containing 40 g or 400 g granules.
Vrečice iz laminirane aluminijeve folije, ki vsebujejo po 40 g ali 400 g.
ALUMINIUM FOIL USED FOR SEALING TRANSPARENT PLASTIC TRAY CONTAINING THE CARTRIDGE
BESEDILO, NATISNJENO NA ALUMINIJSKI FOLIJI, UPORABLJENI ZA ZAPRTJE PROSOJNEGA PLASTIČNEGA LEŽIŠČA, V KATEREM JE VLOŽEK
ALUMINIUM FOIL WRAPPER
OVITEK IZ ALUMINIJASTE FOLIJE
aluminium foil/ polyester laminated bag
Vrečka (Alu/PE)
Aluminium foil/polyester laminated bag containing 500 g – oral powder
vreča iz laminirane aluminijeve folije in poliestra, ki vsebuje 500 g – peroralni prašek
Aluminium hydroxide .....................................................................................5.29 mg (aluminium)
aluminijev hidroksid.............................................................................................5,29 mg (aluminij)
Aluminium hydroxide 1.8 - 2.2 mg
Aluminijev hidroksid 1,8–2,2 mg
Aluminium hydroxide 1.8–2.2 mg
Aluminijev hidroksid 1,8–2,2 mg
Aluminium hydroxide 1.8–2.2 mg.
aluminijev hidroksid 1,8 - 2,2 mg
Aluminium hydroxide 1.8–2.2 mg.
aluminijev hidroksid 1,8 – 2,2 mg
Aluminium hydroxide 2.7 mg,
Aluminijev hidroksid 2,7 mg,
Aluminium hydroxide 2.7 mg, Saponin 30 HU**.
Saponin 30 HE**.
Aluminium hydroxide 4 mg (Al3+)
Aluminijev hidroksid 4 mg (Al3+)
Aluminium hydroxide 4 mg (Al3+), Saponin 1 mg
Aluminijev hidroksid 4 mg (Al3+)
Aluminium hydroxide DEAE-dextran
aluminijev hidroksid DEAE-dekstran
Aluminium hydroxide DEAE-dextran Ginseng Formaldehyde Simethicone
ginseng formaldehid simetikon
Aluminium hydroxide max.
Aluminijev hidroksid najv.
Aluminium hydroxide Mineral oil (Marcol 52)
Aluminijev hidroksid
Aluminium hydroxide Purified saponin (Quil A) Thiomersal
Aluminijev hidroksid Prečiščen saponin (Quil A) Tiomersal